Hims & Hers Health Stock Plummets 3.59% Amidst $106.5 Million Trading Volume and 93rd Ranking in Market Activity

On July 17, 2025, Hims & Hers Health (HIMS) experienced a trading volume of $106.5 million, ranking 93rd in the day's stock market activity. The company's stock price decreased by 3.59%.

Hims & Hers Health, Inc. is currently facing multiple securities class actions due to allegations of deceptive marketing practices related to Wegovy®. The complaints suggest that the company was involved in the promotion and sale of illegitimate, knockoff versions of Wegovy®, which posed risks to patient safety. This has raised concerns about the potential termination of Hims' collaboration with Novo Nordisk, a significant partner in their operations.

Shareholders who purchased HIMS shares between April 29, 2025, and June 23, 2025, are encouraged to contact legal firms to discuss potential lead plaintiff appointments. The deadline for shareholders to register for this class action is August 25, 2025. The allegations include claims that Hims' statements about its business, operations, and prospects were materially misleading during the class period.

Novo Nordisk has terminated its partnership with Hims & Hers, citing deceptive marketing practices. This development has further impacted investor confidence in the company, contributing to the recent decline in its stock price. The allegations against Hims & Hers include the use of deceptive marketing practices and the promotion of compounded GLP-1 drugs from overseas suppliers, which were not approved by regulatory authorities.